NCT07168317View on ClinicalTrials.gov

Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

August 1, 2028

Study Completion Date

August 1, 2028

Conditions
New Diagnosed Angioimmunoblastic T-Cell Lymphoma
Interventions
DRUG

tislelizumab in combination with cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone

tislelizumab: 200mg on d1 every 3 weeks; chidamide: 20mg twice a week at least 3 days apart; cyclophosphamide: 750mg/m2 on Day 1 of each cycle, every 4 weeks; mitoxantrone liposomes: 20mg/m2 on Day 1, every 4 weeks; prednisone: 100mg/day on Day 1 to Day 5 of each course, every 4 weeks.

Trial Locations (1)

221000

RECRUITING

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

All Listed Sponsors
lead

The Affiliated Hospital of Xuzhou Medical University

OTHER

NCT07168317 - Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL | Biotech Hunter | Biotech Hunter